# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Duke Kahanamoku (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML050-SYN
- Date: 2026-04-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kawika Lindgren-Morrison, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review, five days after the sick visit. **S**

## History of present illness

Mr. Kahanamoku returns two weeks after spironolactone was added and five days after his sick visit for vomiting and diarrhea, when his potassium was 5.5 mmol/L. He followed the sick-day card: he held empagliflozin, furosemide, spironolactone and sacubitril-valsartan, took half-dose carvedilol for two days and drank oral rehydration solution. The illness settled after three days, and he restarted all his medicines two days ago. His home weight is 93 kg and steady, he has no swelling, orthopnea or lightheadedness, and he walks a mile on the flat without stopping. He is eager to be back in the ocean and asks how to do it safely. **S**

| Element | Detail |
|---|---|
| Since the sick visit | Medicines held for three days, restarted two days ago; no further vomiting or diarrhea |
| Home weight | 93 kg, steady |
| Function | Walks a mile on the flat; NYHA class II |
| KCCQ-12 | 66, from 56 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No vomiting or diarrhea since three days ago; eating normally |
| Cardiovascular | Negative | No chest pain, palpitations, ankle swelling or lightheadedness |
| Respiratory | Negative | No breathlessness at rest; sleeps flat |
| Musculoskeletal | Negative | No muscle aches on atorvastatin 80 mg |

4 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Atorvastatin 80 mg oral tablet, one tablet daily **S**
- Furosemide 20 mg oral tablet, one tablet every morning **S**
- Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril **S**
- Carvedilol 12.5 mg oral tablet, one tablet twice daily with food **S**
- Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking **S**
- Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 68 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 93 kg; BMI 27.2 kg/m². All vital signs are synthetic.

Sodium: 137 mmol/L; Potassium: 4.8 mmol/L; Creatinine: 1.2 mg/dL; eGFR (CKD-EPI 2021): 67 mL/min/1.73 m²; Glucose: 97 mg/dL; Magnesium: 2 mg/dL; Total cholesterol: 130 mg/dL; LDL cholesterol: 62 mg/dL; HDL cholesterol: 45 mg/dL; Triglycerides: 115 mg/dL; ALT: 31 U/L; KCCQ-12 overall summary: 66. All results are synthetic.

## Change since baseline

- Sodium: 138 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.8 mmol/L at this visit **S**
- Creatinine: 1.02 mg/dL at baseline, 1.2 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 81 mL/min/1.73 m² at baseline, 67 mL/min/1.73 m² at this visit **S**
- Glucose: 102 mg/dL (high) at baseline, 97 mg/dL at this visit **S**
- Magnesium: 2 mg/dL at baseline, 2 mg/dL at this visit **S**
- Total cholesterol: 168 mg/dL at baseline, 130 mg/dL at this visit **S**
- LDL cholesterol: 92 mg/dL (high) at baseline, 62 mg/dL at this visit **S**
- HDL cholesterol: 44 mg/dL at baseline, 45 mg/dL at this visit **S**
- Triglycerides: 160 mg/dL (high) at baseline, 115 mg/dL at this visit **S**
- ALT: 28 U/L at baseline, 31 U/L at this visit **S**
- KCCQ-12 overall summary: 38 at baseline, 66 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 112/70, pulse 68; weight 93.0 kg |
| Orthostatic vital signs | Standing at three minutes 108/68 mmHg without symptoms |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; no S3; apical systolic murmur |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with reduced ejection fraction** (I50.22). Euvolemic at a dry weight of about 93 kg, NYHA class II, KCCQ-12 66. Potassium 4.8 mmol/L and creatinine 1.20 mg/dL (eGFR 67) two days after restarting, back near baseline, so the sick-day rules worked. Pulse 68 and blood pressure 112/70 allow a beta-blocker increase; one change at a time after the illness. **S**
   - Raise carvedilol to 12.5 mg twice daily.
   - Reduce furosemide to 20 mg daily now that he is dry.
   - Raise sacubitril-valsartan to 49/51 mg twice daily in two weeks by the heart failure nurse, with a metabolic panel one week after that change.
   - Continue empagliflozin and spironolactone 12.5 mg.
2. **Coronary artery disease** (I25.2). LDL 62 mg/dL six weeks after atorvastatin was raised to 80 mg, at goal; ALT 31 U/L. **S**
   - Continue atorvastatin 80 mg and aspirin 81 mg.
3. **Exercise and the ocean**. He will be eligible for cardiac rehabilitation for heart failure in about four weeks, six weeks after his angiography and his last new medicine. **S**
   - Cardiac rehabilitation, 36 sessions, from late May, with pool swimming once the team agrees.
   - Until then, walking only; no swimming or surfing yet.
   - Ocean plan after rehabilitation: calm water inside the reef, with a companion and near a lifeguard; no breath-hold diving; no big surf until cleared; water through the morning; out of the water at once for chest pain, lightheadedness or unusual breathlessness.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and heart rate (seated and standing) | Every visit | Completed today | 112/70 mmHg, pulse 68; standing 108/68 without symptoms |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 93.0 kg; jugular venous pressure not raised; no edema; NYHA II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, ARNI, MRA or SGLT2 inhibitor; then every three to six months | Completed today | Two weeks after spironolactone and two days after restarting held medicines: sodium 137, potassium 4.8, creatinine 1.20 mg/dL (eGFR 67), magnesium 2.0. The one-to-two-week check after spironolactone was also covered by the sick-visit panel at nine days (potassium 5.5 during volume depletion) |
| Medication safety | Guideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target doses | Every two weeks during titration | Completed today | Carvedilol raised today; sacubitril-valsartan increase planned in two weeks by the nurse, with a panel a week later |
| Medication safety | MRA and ARNI: potassium and kidney function during illness | Every visit | Completed today | Sick-day rules used correctly; potassium back to 4.8 |
| Laboratory | Lipid panel | Four to twelve weeks after a statin change, then every three to twelve months | Completed today | Six weeks after atorvastatin 80 mg: LDL 62 mg/dL, total cholesterol 130, HDL 45, triglycerides 115; ALT 31 U/L |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 66, from 56 |
| Imaging | Echocardiogram | At diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained change | Not indicated | Repeat after three to six months of optimized therapy |
| Examination | Primary-prevention ICD evaluation (and CRT if QRS is wide) | After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarction | Due | After at least 90 days of optimized therapy |
| Referral | Cardiac rehabilitation for heart failure | When eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeks | Ordered | Program booked from late May, when he becomes eligible |
| Self-management | Self-care: daily weights, sodium, sick-day rules and symptoms to report | Every visit | Completed today | Sick-day card used well; daily weights; dry weight 93 kg |
| Self-management | Culturally safe care: ʻohana involvement as he chooses; his own healing practices | Every visit | Completed today | No Native Hawaiian practices raised today; offer remains open |

## Goal progress

- Euvolemia: no ankle swelling or orthopnea, with a steady dry weight. Outcome by 2026-04-27: Dry weight about 93 kg; no edema or orthopnea; furosemide reduced to 20 mg. **S**
- All four guideline-directed medicines at the highest doses he tolerates within three months. In progress; target 2026-09-28. **S**
- KCCQ-12 at least 20 points higher and NYHA class I to II within six months. In progress; target 2026-09-28. **S**
- Back in the ocean safely, swimming in calm water with a companion. In progress; target 2026-09-28. **S**
- LDL cholesterol below 70 mg/dL. Outcome by 2026-04-27: LDL 62 mg/dL on atorvastatin 80 mg. **S**

## Medication changes

- Stopped: Furosemide 40 mg oral tablet, one tablet every morning **S**
- Started: Furosemide 20 mg oral tablet, one tablet every morning **S**
- Stopped: Carvedilol 6.25 mg oral tablet, one tablet twice daily with food **S**
- Started: Carvedilol 12.5 mg oral tablet, one tablet twice daily with food **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America (Circulation 2022;145(18):e895-e1032)
- 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024), American College of Cardiology (J Am Coll Cardiol 2024;83(15):1444-1488)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026), Aether Forge

## Follow-up

- Heart failure nurse call in two weeks to raise sacubitril-valsartan, with a metabolic panel one week later. Cardiac rehabilitation from late May. Annual wellness visit in September; heart failure review in about five months with a repeat echocardiogram. **S**
- Next scheduled visit 2026-09-14: subsequent annual wellness visit. **S**
